Key clinical point: T2 relaxation time of uterine fibroids (UF) obtained before treatment with magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was an important predictor of nonperfused volume ratio (NPVr) and outperformed existing T2-weighted imaging methods like Funaki classification.

Major finding: T2 relaxation time correlated negatively with NPVr (correlation coefficient, −0.54; P < .001). The area under the curve value was higher for T2 relaxation time classification (T2 I, 0.69; T2 II, 0.69; and T2 III, 0.84; whole model P = .0019) vs corresponding Funaki classification (Funaki I, 0.57; Funaki II, 0.40; and Funaki III, 0.66; P = 0.56).

Study details: Findings are from a prospective analysis of 30 women with 32 UFs who underwent T2 relaxation time mapping before MRgHIFU treatment.

Disclosures: This study was funded by The Finnish Cultural Foundation, TYKS Foundation, and Instrumentarium Science Foundation. The authors declared no conflict of interests.

Source: Sainio T et al. Int J Hyperthermia. 2021 Sep 19. doi: 10.1080/02656736.2021.1976850.

Key clinical point: T2 relaxation time of uterine fibroids (UF) obtained before treatment with magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was an important predictor of nonperfused volume ratio (NPVr) and outperformed existing T2-weighted imaging methods like Funaki classification.

Major finding: T2 relaxation time correlated negatively with NPVr (correlation coefficient, −0.54; P < .001). The area under the curve value was higher for T2 relaxation time classification (T2 I, 0.69; T2 II, 0.69; and T2 III, 0.84; whole model P = .0019) vs corresponding Funaki classification (Funaki I, 0.57; Funaki II, 0.40; and Funaki III, 0.66; P = 0.56).

Study details: Findings are from a prospective analysis of 30 women with 32 UFs who underwent T2 relaxation time mapping before MRgHIFU treatment.

Disclosures: This study was funded by The Finnish Cultural Foundation, TYKS Foundation, and Instrumentarium Science Foundation. The authors declared no conflict of interests.

Source: Sainio T et al. Int J Hyperthermia. 2021 Sep 19. doi: 10.1080/02656736.2021.1976850.

Key clinical point: T2 relaxation time of uterine fibroids (UF) obtained before treatment with magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was an important predictor of nonperfused volume ratio (NPVr) and outperformed existing T2-weighted imaging methods like Funaki classification.

Major finding: T2 relaxation time correlated negatively with NPVr (correlation coefficient, −0.54; P < .001). The area under the curve value was higher for T2 relaxation time classification (T2 I, 0.69; T2 II, 0.69; and T2 III, 0.84; whole model P = .0019) vs corresponding Funaki classification (Funaki I, 0.57; Funaki II, 0.40; and Funaki III, 0.66; P = 0.56).

Study details: Findings are from a prospective analysis of 30 women with 32 UFs who underwent T2 relaxation time mapping before MRgHIFU treatment.

Disclosures: This study was funded by The Finnish Cultural Foundation, TYKS Foundation, and Instrumentarium Science Foundation. The authors declared no conflict of interests.

Source: Sainio T et al. Int J Hyperthermia. 2021 Sep 19. doi: 10.1080/02656736.2021.1976850.

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771.

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771.

Key clinical point: Patients with psoriasis showed lower coronary inflammation and higher atherosclerotic burden than matched control participants.

Major finding: Compared with cardiovascular disease (CVD) risk factor-matched control participants, patients with psoriasis showed a lower perivascular fat attenuation index (−80.19 ± 7.48 vs −78.14 ± 7.81 Hounsfield unit; P less than .001), indicating lower coronary inflammation and a higher overall computed tomography-adapted Leaman score (5.86 vs 4.69; P = .030).

Study details: This was a retrospective, single-center study including 98 patients with psoriasis and 196 CVD risk factor-matched control participants.

Disclosures: No specific funding for the study was disclosed. Z Xu declared being an employee of Siemens Healthineers CT Collaboration. No other potential conflict of interests was declared.

Source: Bao W et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518771.

Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the long-term.

Major finding: Switching of first- and second-line biologics was likely attributed to a secondary lack of efficacy for skin disease. Each unit increase in age decreased the likelihood of switching twice or more by 4% (odds ratio [OR], 0.964; P = .038), whereas the existence of PsA increased the likelihood by 2.69-fold (OR, 2.69; P = .026).

Study details: This was a retrospective study including 115 adult patients with psoriasis who had been receiving biologics for 12 consecutive months or more and underwent at least a single biologic switch.

Disclosures: No specific funding for the study was disclosed. The authors declared no potential conflict of interests.

Source: Akdogan N et al. Expert Rev Clin Pharmacol. 2021 Sep 23. doi: 10.1080/17512433.2021.1979394.

Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the long-term.

Major finding: Switching of first- and second-line biologics was likely attributed to a secondary lack of efficacy for skin disease. Each unit increase in age decreased the likelihood of switching twice or more by 4% (odds ratio [OR], 0.964; P = .038), whereas the existence of PsA increased the likelihood by 2.69-fold (OR, 2.69; P = .026).

Study details: This was a retrospective study including 115 adult patients with psoriasis who had been receiving biologics for 12 consecutive months or more and underwent at least a single biologic switch.

Disclosures: No specific funding for the study was disclosed. The authors declared no potential conflict of interests.

Source: Akdogan N et al. Expert Rev Clin Pharmacol. 2021 Sep 23. doi: 10.1080/17512433.2021.1979394.

Key clinical point: Switching biologics in patients with psoriasis was mostly impelled by secondary lack of efficacy for skin symptoms with young age and the presence of psoriatic arthritis (PsA) linked to a higher frequency of switching in the long-term.

Major finding: Switching of first- and second-line biologics was likely attributed to a secondary lack of efficacy for skin disease. Each unit increase in age decreased the likelihood of switching twice or more by 4% (odds ratio [OR], 0.964; P = .038), whereas the existence of PsA increased the likelihood by 2.69-fold (OR, 2.69; P = .026).

Study details: This was a retrospective study including 115 adult patients with psoriasis who had been receiving biologics for 12 consecutive months or more and underwent at least a single biologic switch.

Disclosures: No specific funding for the study was disclosed. The authors declared no potential conflict of interests.

Source: Akdogan N et al. Expert Rev Clin Pharmacol. 2021 Sep 23. doi: 10.1080/17512433.2021.1979394.

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685.

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685.

Key clinical point: This real-life study showed reduced efficacy of guselkumab for over 36 weeks in patients with moderate-to-severe chronic plaque psoriasis than previously reported, with body weight and exposure to biologics being the major predictors of response.

Major finding: At week 36, 67% of patients achieved Psoriasis Area Severity Index (PASI) 75 with heavier vs. low‐weight patients showing a decreased likelihood of achieving PASI 75 until week 4 (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.88-0.99). Even at week 36, PASI 75 response rates were lower for patients exposed to 1 (OR, 0.07; 95% CI, 0.00-0.68) or more than 1 (OR, 0.00; 95% CI, 0.00-0.044) biologics than for biologic-naïve patients.

Study details: Findings are from a multicenter retrospective cohort study including 135 adult patients with moderate-to-severe chronic plaque psoriasis.

Disclosures: The study was supported by the Chang Gung Memorial Hospital and National Taiwan University Hospital, Hsin-Chu branch. Some of the authors declared serving as clinical trial participant or receiving speaker/consultancy honoraria from various sources.

Source: Hung YT et al. Ther Adv Chronic Dis. 2021 Sep 29. doi: 10.1177/20406223211046685.

Key clinical point: Patients with positive fecal immunochemistry test (FIT) results showed a significantly higher risk for psoriasis than those who were FIT-negative.

Major finding: During a 6.68-year median follow-up, the incidence rate of psoriasis per 1000 person-years was higher for the FIT-positive vs the FIT-negative group (4.14 vs 3.76). After multivariable adjustment, the adjusted hazard ratios for psoriasis were 1.029 (95% confidence interval [CI], 0.997-1.061), 1.118 (95% CI, 1.04-1.201), and 1.342 (95% CI, 1.157-1.557) for 1, 2, and 3 positive FIT results, respectively, vs negative FIT results.

Study details: Findings are from a retrospective nationwide population-based study of 1,395,147 participants aged 50 years or above who underwent screening for colorectal cancer.

Disclosures: The study was supported by the New Faculty Startup Fund from Seoul National University. The authors declared no potential conflict of interests.

Source: Lee HJ et al. Dermatology. 2021 Sep 16. doi: 10.1159/000518625.

Key clinical point: Patients with positive fecal immunochemistry test (FIT) results showed a significantly higher risk for psoriasis than those who were FIT-negative.

Major finding: During a 6.68-year median follow-up, the incidence rate of psoriasis per 1000 person-years was higher for the FIT-positive vs the FIT-negative group (4.14 vs 3.76). After multivariable adjustment, the adjusted hazard ratios for psoriasis were 1.029 (95% confidence interval [CI], 0.997-1.061), 1.118 (95% CI, 1.04-1.201), and 1.342 (95% CI, 1.157-1.557) for 1, 2, and 3 positive FIT results, respectively, vs negative FIT results.

Study details: Findings are from a retrospective nationwide population-based study of 1,395,147 participants aged 50 years or above who underwent screening for colorectal cancer.

Disclosures: The study was supported by the New Faculty Startup Fund from Seoul National University. The authors declared no potential conflict of interests.

Source: Lee HJ et al. Dermatology. 2021 Sep 16. doi: 10.1159/000518625.

Key clinical point: Patients with positive fecal immunochemistry test (FIT) results showed a significantly higher risk for psoriasis than those who were FIT-negative.

Major finding: During a 6.68-year median follow-up, the incidence rate of psoriasis per 1000 person-years was higher for the FIT-positive vs the FIT-negative group (4.14 vs 3.76). After multivariable adjustment, the adjusted hazard ratios for psoriasis were 1.029 (95% confidence interval [CI], 0.997-1.061), 1.118 (95% CI, 1.04-1.201), and 1.342 (95% CI, 1.157-1.557) for 1, 2, and 3 positive FIT results, respectively, vs negative FIT results.

Study details: Findings are from a retrospective nationwide population-based study of 1,395,147 participants aged 50 years or above who underwent screening for colorectal cancer.

Disclosures: The study was supported by the New Faculty Startup Fund from Seoul National University. The authors declared no potential conflict of interests.

Source: Lee HJ et al. Dermatology. 2021 Sep 16. doi: 10.1159/000518625.

Key clinical point: Guselkumab positively affected both clinician- and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis, irrespective of their history of psoriasis therapies.

Major finding: After 28 weeks, 56.8% of patients attained a Dermatology Life Quality Index (DLQI) score of 1 or less, with the mean DLQI score decreasing from 13.7 at baseline to 2.8 (95% confidence interval [CI], 2.3-3.2), and mean Psoriasis Area Severity Index (PASI) decreasing from 16.4 at baseline to 3.0 (95% CI, 2.3-3.6), with a 55.3% PASI 90 response rate. Most adverse events were mild or moderate.

Study details: The data come from PERSIST, an ongoing, prospective, real-life study that enrolled 303 patients aged 18 years or above with moderate-to-severe plaque psoriasis for 2 years or more who were prescribed guselkumab.

Disclosures: This study was supported by Janssen-Cilag GmbH (Germany). S Wegner, Y Personke, and M Gomez reported being employees of Janssen-Cilag, whereas the other authors declared serving as an advisor, speaker, or clinical trial participant or receiving grants from various companies including Janssen-Cilag.

Source: Gerdes S et al. J Dermatol. 2021 Sep 12. doi: 10.1111/1346-8138.16128.

Key clinical point: Guselkumab positively affected both clinician- and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis, irrespective of their history of psoriasis therapies.

Major finding: After 28 weeks, 56.8% of patients attained a Dermatology Life Quality Index (DLQI) score of 1 or less, with the mean DLQI score decreasing from 13.7 at baseline to 2.8 (95% confidence interval [CI], 2.3-3.2), and mean Psoriasis Area Severity Index (PASI) decreasing from 16.4 at baseline to 3.0 (95% CI, 2.3-3.6), with a 55.3% PASI 90 response rate. Most adverse events were mild or moderate.

Study details: The data come from PERSIST, an ongoing, prospective, real-life study that enrolled 303 patients aged 18 years or above with moderate-to-severe plaque psoriasis for 2 years or more who were prescribed guselkumab.

Disclosures: This study was supported by Janssen-Cilag GmbH (Germany). S Wegner, Y Personke, and M Gomez reported being employees of Janssen-Cilag, whereas the other authors declared serving as an advisor, speaker, or clinical trial participant or receiving grants from various companies including Janssen-Cilag.

Source: Gerdes S et al. J Dermatol. 2021 Sep 12. doi: 10.1111/1346-8138.16128.

Key clinical point: Guselkumab positively affected both clinician- and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis, irrespective of their history of psoriasis therapies.

Major finding: After 28 weeks, 56.8% of patients attained a Dermatology Life Quality Index (DLQI) score of 1 or less, with the mean DLQI score decreasing from 13.7 at baseline to 2.8 (95% confidence interval [CI], 2.3-3.2), and mean Psoriasis Area Severity Index (PASI) decreasing from 16.4 at baseline to 3.0 (95% CI, 2.3-3.6), with a 55.3% PASI 90 response rate. Most adverse events were mild or moderate.

Study details: The data come from PERSIST, an ongoing, prospective, real-life study that enrolled 303 patients aged 18 years or above with moderate-to-severe plaque psoriasis for 2 years or more who were prescribed guselkumab.

Disclosures: This study was supported by Janssen-Cilag GmbH (Germany). S Wegner, Y Personke, and M Gomez reported being employees of Janssen-Cilag, whereas the other authors declared serving as an advisor, speaker, or clinical trial participant or receiving grants from various companies including Janssen-Cilag.

Source: Gerdes S et al. J Dermatol. 2021 Sep 12. doi: 10.1111/1346-8138.16128.

Key clinical point: Periodontitis serves as an independent risk factor for psoriasis and in combination with smoking synergistically contributes to psoriasis development.

Major finding: The risk for psoriasis was higher in patients with vs. without periodontitis (adjusted hazard ratio [aHR], 1.116; 95% confidence interval [CI], 1.101-1.13). Compared with nonsmokers without periodontitis, the risk for psoriasis in nonsmokers with periodontitis and smokers with periodontitis increased by 11% (aHR, 1.11; 95% CI, 1.094-1.127) and 26.5% (aHR, 1.265; 95% CI, 1.234-1.296), respectively.

Study details: The data come from a 9-year follow-up, nationwide, population-based cohort study that included 1,063,004 and 8,655,587 patients with and without periodontitis, respectively, and not pre-diagnosed with psoriasis.

Disclosures: The study was supported by a National Research Foundation of Korea grant funded by the Korean government. The authors declared no potential conflict of interests.

Source: Han JH et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518296.

Key clinical point: Periodontitis serves as an independent risk factor for psoriasis and in combination with smoking synergistically contributes to psoriasis development.

Major finding: The risk for psoriasis was higher in patients with vs. without periodontitis (adjusted hazard ratio [aHR], 1.116; 95% confidence interval [CI], 1.101-1.13). Compared with nonsmokers without periodontitis, the risk for psoriasis in nonsmokers with periodontitis and smokers with periodontitis increased by 11% (aHR, 1.11; 95% CI, 1.094-1.127) and 26.5% (aHR, 1.265; 95% CI, 1.234-1.296), respectively.

Study details: The data come from a 9-year follow-up, nationwide, population-based cohort study that included 1,063,004 and 8,655,587 patients with and without periodontitis, respectively, and not pre-diagnosed with psoriasis.

Disclosures: The study was supported by a National Research Foundation of Korea grant funded by the Korean government. The authors declared no potential conflict of interests.

Source: Han JH et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518296.

Key clinical point: Periodontitis serves as an independent risk factor for psoriasis and in combination with smoking synergistically contributes to psoriasis development.

Major finding: The risk for psoriasis was higher in patients with vs. without periodontitis (adjusted hazard ratio [aHR], 1.116; 95% confidence interval [CI], 1.101-1.13). Compared with nonsmokers without periodontitis, the risk for psoriasis in nonsmokers with periodontitis and smokers with periodontitis increased by 11% (aHR, 1.11; 95% CI, 1.094-1.127) and 26.5% (aHR, 1.265; 95% CI, 1.234-1.296), respectively.

Study details: The data come from a 9-year follow-up, nationwide, population-based cohort study that included 1,063,004 and 8,655,587 patients with and without periodontitis, respectively, and not pre-diagnosed with psoriasis.

Disclosures: The study was supported by a National Research Foundation of Korea grant funded by the Korean government. The authors declared no potential conflict of interests.

Source: Han JH et al. Dermatology. 2021 Sep 15. doi: 10.1159/000518296.

Key clinical point: Proactive management with calcipotriene 50 μg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) foam vs. reactive management with vehicle foam decreased the severity of patient-reported symptoms in patients with plaque psoriasis.

Major finding: Proactive vs. reactive management during 52-week maintenance showed greater improvement in Psoriasis Symptom Inventory (difference, −0.75; P = .0128) and Dermatology Life Quality Index (difference −0.45; P = .007) and nonsignificantly higher EuroQol-5D for psoriasis (0.89 vs 0.88; P = .0842) scores.

Study details: Findings are from a post hoc analysis of phase 3 PSO-LONG trial including 521 patients with plaque psoriasis randomly assigned to proactive management (Cal/BD foam twice weekly) or reactive management (vehicle foam twice weekly) arms.

Disclosures: The study was sponsored by Leo Pharma. The authors declared serving as consultants, advisory board members, and clinical trial investigators or receiving grants/speaker honoraria from various sources, including LEO Pharma.

Source: Jalili A et al. J Eur Acad Dermatol Venereol. 2021 Sep 20. doi: 10.1111/jdv.17673.

Key clinical point: Proactive management with calcipotriene 50 μg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) foam vs. reactive management with vehicle foam decreased the severity of patient-reported symptoms in patients with plaque psoriasis.

Major finding: Proactive vs. reactive management during 52-week maintenance showed greater improvement in Psoriasis Symptom Inventory (difference, −0.75; P = .0128) and Dermatology Life Quality Index (difference −0.45; P = .007) and nonsignificantly higher EuroQol-5D for psoriasis (0.89 vs 0.88; P = .0842) scores.

Study details: Findings are from a post hoc analysis of phase 3 PSO-LONG trial including 521 patients with plaque psoriasis randomly assigned to proactive management (Cal/BD foam twice weekly) or reactive management (vehicle foam twice weekly) arms.

Disclosures: The study was sponsored by Leo Pharma. The authors declared serving as consultants, advisory board members, and clinical trial investigators or receiving grants/speaker honoraria from various sources, including LEO Pharma.

Source: Jalili A et al. J Eur Acad Dermatol Venereol. 2021 Sep 20. doi: 10.1111/jdv.17673.

Key clinical point: Proactive management with calcipotriene 50 μg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) foam vs. reactive management with vehicle foam decreased the severity of patient-reported symptoms in patients with plaque psoriasis.

Major finding: Proactive vs. reactive management during 52-week maintenance showed greater improvement in Psoriasis Symptom Inventory (difference, −0.75; P = .0128) and Dermatology Life Quality Index (difference −0.45; P = .007) and nonsignificantly higher EuroQol-5D for psoriasis (0.89 vs 0.88; P = .0842) scores.

Study details: Findings are from a post hoc analysis of phase 3 PSO-LONG trial including 521 patients with plaque psoriasis randomly assigned to proactive management (Cal/BD foam twice weekly) or reactive management (vehicle foam twice weekly) arms.

Disclosures: The study was sponsored by Leo Pharma. The authors declared serving as consultants, advisory board members, and clinical trial investigators or receiving grants/speaker honoraria from various sources, including LEO Pharma.

Source: Jalili A et al. J Eur Acad Dermatol Venereol. 2021 Sep 20. doi: 10.1111/jdv.17673.

Key clinical point: The disease severity assessment, guiding initiation of systemic therapy, differed when either patient- or clinician-reported outcomes were considered alone, highlighting the complementary value of both for appropriate treatment.

Major finding: Overall, 72.4% (95% confidence interval [CI], 67.3%-77.0%) of patients who qualified for systemic therapy initiation on account of Psoriasis Area Severity Index (PASI) scores or body surface area (BSA) of 10 or higher had a Dermatology Life Quality Index (DLQI) score of less than 10. Conversely, 10.4% (95% CI, 8.8%-12.1%) of patients with a DLQI score higher than 10 did not qualify for systemic therapy based on PASI scores or BSA.

Study details: Findings are from a cross-sectional, observational study including 1,733 patients with mild, moderate, or severe psoriasis who met the criteria for initiation of systemic therapy based on DLQI score, PASI score, or BSA.

Disclosures: No specific funding for the study was disclosed. Dr. Gelfand declared receiving consultation fees and research grants from various sources.

Source: Barbieri JS et al. JAMA Dermatol. 2021 Sep 8. doi: 10.1001/jamadermatol.2021.3341.

Key clinical point: The disease severity assessment, guiding initiation of systemic therapy, differed when either patient- or clinician-reported outcomes were considered alone, highlighting the complementary value of both for appropriate treatment.

Major finding: Overall, 72.4% (95% confidence interval [CI], 67.3%-77.0%) of patients who qualified for systemic therapy initiation on account of Psoriasis Area Severity Index (PASI) scores or body surface area (BSA) of 10 or higher had a Dermatology Life Quality Index (DLQI) score of less than 10. Conversely, 10.4% (95% CI, 8.8%-12.1%) of patients with a DLQI score higher than 10 did not qualify for systemic therapy based on PASI scores or BSA.

Study details: Findings are from a cross-sectional, observational study including 1,733 patients with mild, moderate, or severe psoriasis who met the criteria for initiation of systemic therapy based on DLQI score, PASI score, or BSA.

Disclosures: No specific funding for the study was disclosed. Dr. Gelfand declared receiving consultation fees and research grants from various sources.

Source: Barbieri JS et al. JAMA Dermatol. 2021 Sep 8. doi: 10.1001/jamadermatol.2021.3341.

Key clinical point: The disease severity assessment, guiding initiation of systemic therapy, differed when either patient- or clinician-reported outcomes were considered alone, highlighting the complementary value of both for appropriate treatment.

Major finding: Overall, 72.4% (95% confidence interval [CI], 67.3%-77.0%) of patients who qualified for systemic therapy initiation on account of Psoriasis Area Severity Index (PASI) scores or body surface area (BSA) of 10 or higher had a Dermatology Life Quality Index (DLQI) score of less than 10. Conversely, 10.4% (95% CI, 8.8%-12.1%) of patients with a DLQI score higher than 10 did not qualify for systemic therapy based on PASI scores or BSA.

Study details: Findings are from a cross-sectional, observational study including 1,733 patients with mild, moderate, or severe psoriasis who met the criteria for initiation of systemic therapy based on DLQI score, PASI score, or BSA.

Disclosures: No specific funding for the study was disclosed. Dr. Gelfand declared receiving consultation fees and research grants from various sources.

Source: Barbieri JS et al. JAMA Dermatol. 2021 Sep 8. doi: 10.1001/jamadermatol.2021.3341.

Key clinical point: Risankizumab displayed superior long-term clinical efficacy against moderate-to-severe psoriasis, with no new safety signals in the 52-week update of a multicenter real-life study.

Major finding: Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at week 36 were 92.7%, 83.6%, and 65.5%, which were maintained through week 52 at 96.4%, 85.5%, and 60.0%, respectively. Unlike in phase 3 trials, more biologic-experienced patients reached PASI 100 at weeks 36 and 52 (71.8% and 69.2%, respectively) compared with biologic-naïve patients (50.0% and 37.5%, respectively).

Study details: Findings are from a real-life multicenter study including 57 adult patients with moderate-to-severe psoriasis who were receiving risankizumab therapy.

Disclosures: The study did not receive any funding. Some of the authors including the lead author declared receiving consultation/personal fees or research grants from various sources.

Source: Hansel K et al. J Eur Acad Dermatol Venereol. 2021 Sep 12. doi: 10.1111/jdv.17656.

Key clinical point: Risankizumab displayed superior long-term clinical efficacy against moderate-to-severe psoriasis, with no new safety signals in the 52-week update of a multicenter real-life study.

Major finding: Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at week 36 were 92.7%, 83.6%, and 65.5%, which were maintained through week 52 at 96.4%, 85.5%, and 60.0%, respectively. Unlike in phase 3 trials, more biologic-experienced patients reached PASI 100 at weeks 36 and 52 (71.8% and 69.2%, respectively) compared with biologic-naïve patients (50.0% and 37.5%, respectively).

Study details: Findings are from a real-life multicenter study including 57 adult patients with moderate-to-severe psoriasis who were receiving risankizumab therapy.

Disclosures: The study did not receive any funding. Some of the authors including the lead author declared receiving consultation/personal fees or research grants from various sources.

Source: Hansel K et al. J Eur Acad Dermatol Venereol. 2021 Sep 12. doi: 10.1111/jdv.17656.

Key clinical point: Risankizumab displayed superior long-term clinical efficacy against moderate-to-severe psoriasis, with no new safety signals in the 52-week update of a multicenter real-life study.

Major finding: Psoriasis Area and Severity Index (PASI) 75, PASI 90, and PASI 100 response rates at week 36 were 92.7%, 83.6%, and 65.5%, which were maintained through week 52 at 96.4%, 85.5%, and 60.0%, respectively. Unlike in phase 3 trials, more biologic-experienced patients reached PASI 100 at weeks 36 and 52 (71.8% and 69.2%, respectively) compared with biologic-naïve patients (50.0% and 37.5%, respectively).

Study details: Findings are from a real-life multicenter study including 57 adult patients with moderate-to-severe psoriasis who were receiving risankizumab therapy.

Disclosures: The study did not receive any funding. Some of the authors including the lead author declared receiving consultation/personal fees or research grants from various sources.

Source: Hansel K et al. J Eur Acad Dermatol Venereol. 2021 Sep 12. doi: 10.1111/jdv.17656.